LCTX
Lineage Cell Therapeutics, Inc.
NYSE American · usd
Lineage Cell Therapeutics, Inc. (LCTX) trades at $0.8385 (+2.78%) as of 7:30:02 PM EST on Nov 18, 2026, -13.79% over the past month. Market cap is $206.36M, with 19.3 days to cover in short interest.
Stock performance
How Lineage Cell Therapeutics, Inc. (LCTX) stock has performed from one day to one year, with its 52-week range.
- 1D
- +2.78%
- 1W
- -24.46%
- 1M
- -13.79%
- YTD
- -49.79%
- 1Y
- -50.96%
- 52-wk range
- $0.77 – $1.99
Key statistics
Today's trading snapshot for LCTX: day range, open, previous close, volume and market cap.
- Day range
- $0.82 – $0.86
- Open
- $0.82
- Prev close
- $0.82
- Volume
- 1.22M
- Market cap
- $206.36M
- Shares out
- 252.95M
Valuation and profitability ratios: P/E, P/S, ROE
Valuation and profitability ratios for Lineage Cell Therapeutics, Inc.: P/E, P/S, P/B, ROE and more.
- P/E
- 118.32
- P/S
- 19.14
- P/B
- 3.09
- P/FCF
- —
- ROE
- 2.6%
- ROA
- 1.8%
- Debt/Equity
- 0.00
- Div yield
- 0.00%
As of Nov 17, 2026
8-K filings
Material corporate events Lineage Cell Therapeutics, Inc. has disclosed to the SEC on Form 8-K.
- Licensing agreementNov 12, 2026
Under the License Agreement, NeuroAirmid and Lineage ... received an exclusive license under specified patent rights relating to neural stem cell compositions and methods to treat neurodegenerative disorders, and a nonexclusive license to associated technology, to develop, manufacture and commercialize licensed products.
- Deal withdrawalJun 12, 2026
On June 9, 2026, following comments to the application received by the Company from CIRM, the Company elected to withdraw its application for the CIRM Grant. The withdrawal of the application does not impact the Company's current and planned development of OPC1 in the ongoing DOSED clinical study.
- Public offeringMar 11, 2026
On March 11, 2026, Lineage Cell Therapeutics, Inc. (the "Company") filed with the U.S. Securities and Exchange Commission (the "SEC") a prospectus supplement dated March 11, 2026 relating to the offer and sale of the Company's common shares from time to time through or to B. Riley Securities, Inc. ("B. Riley"), pursuant to the sales agreement the Company entered into with B. Riley dated March 22, 2024. The Prospectus Supplement relates to the offer and sale of the Company's common shares under the Sales Agreement having an aggregate offering price of up to $60,000,000 (the "ATM Shares").
- Partnership or collaborationNov 24, 2025
In December 2021, Lineage Cell Therapeutics, Inc. entered into a collaboration and license agreement with Genentech, Inc. and F. Hoffmann-La Roche Ltd. (the 'Roche Agreement') under which our lead cell therapy program known as OpRegen® (also known as RG6501) is being developed for the treatment of ocular disorders, including geographic atrophy ('GA') secondary to age-related macular degeneration ('AMD').
- Strategic initiativeAug 26, 2025
The main objective of the RCA is for the parties to complete a preclinical phase achieving readiness to potentially progress to human clinical trials under one or more separate clinical agreements, representing a material advancement of Lineage's auditory neuronal cell transplant program.
LCTX short interest
How heavily LCTX is shorted: shares short, days to cover and average daily volume.
- Days to cover
- 19.3
- Short interest
- 24.35M
- Avg volume
- 1.26M
As of · reported to FINRA twice monthly.
LCTX news
The latest news and headlines about Lineage Cell Therapeutics, Inc. (LCTX).
- Lineage Cell (LCTX) Reports Q3 Loss, Misses Revenue EstimatesnegativeZacks Investment Research· Nov 12, 2026
- Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative MarketspositiveBenzinga· May 20, 2026
- Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated CellspositiveBenzinga· Apr 10, 2026
- A Key "Master" Protein That Declines by Half After Age 40. One Company Found a Way to Restore It.positiveBenzinga· Mar 18, 2026
- Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell RestorationpositiveBenzinga· Jan 29, 2026
Frequently asked questions
What is the Lineage Cell Therapeutics, Inc. (LCTX) stock price today?
Lineage Cell Therapeutics, Inc. (LCTX) is trading at $0.8385 (+2.78% on the day) as of 7:30:02 PM EST on Nov 18, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.
What is Lineage Cell Therapeutics, Inc.?
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases.
What is the short interest in LCTX?
As of Oct 30, 2026, LCTX has 24.35M shares short and 19.3 days to cover.
What exchange is LCTX listed on?
Lineage Cell Therapeutics, Inc. (LCTX) trades on NYSE American in USD, in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry.
Build with AI
Build an analysis of LCTX with your agent
Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.
Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a LCTX analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.